NO20076232L - Middel for regenerering og/eller besyttelse av nerver - Google Patents

Middel for regenerering og/eller besyttelse av nerver

Info

Publication number
NO20076232L
NO20076232L NO20076232A NO20076232A NO20076232L NO 20076232 L NO20076232 L NO 20076232L NO 20076232 A NO20076232 A NO 20076232A NO 20076232 A NO20076232 A NO 20076232A NO 20076232 L NO20076232 L NO 20076232L
Authority
NO
Norway
Prior art keywords
agonist
effect
regeneration
disease
nerves
Prior art date
Application number
NO20076232A
Other languages
English (en)
Norwegian (no)
Inventor
Kazuyuki Ohmoto
Akihiro Kinoshita
Hidekazu Matsuya
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20076232L publication Critical patent/NO20076232L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20076232A 2005-06-03 2007-12-03 Middel for regenerering og/eller besyttelse av nerver NO20076232L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005164458 2005-06-03
PCT/JP2006/311084 WO2006129788A1 (ja) 2005-06-03 2006-06-02 神経再生および／または保護剤

Publications (1)

Publication Number Publication Date
NO20076232L true NO20076232L (no) 2008-02-28

Family

ID=37481715

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076232A NO20076232L (no) 2005-06-03 2007-12-03 Middel for regenerering og/eller besyttelse av nerver

Country Status (16)

Country Link
US (3) US7863263B2 (ko)
EP (3) EP2494990A1 (ko)
JP (1) JP5040650B2 (ko)
KR (1) KR101320810B1 (ko)
CN (1) CN101237885B (ko)
AU (1) AU2006253356B2 (ko)
BR (1) BRPI0611079A2 (ko)
CA (1) CA2610692C (ko)
ES (1) ES2572755T3 (ko)
IL (2) IL187840A (ko)
NO (1) NO20076232L (ko)
NZ (1) NZ563863A (ko)
RU (1) RU2420316C2 (ko)
TW (1) TWI404529B (ko)
WO (1) WO2006129788A1 (ko)
ZA (1) ZA200710414B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707208A4 (en) 2003-12-05 2010-03-17 Ono Pharmaceutical Co PROMOTER OF BLOOD FLOW IN THE TISSUES OF THE HORSE TAIL
KR101320810B1 (ko) * 2005-06-03 2013-10-21 오노 야꾸힝 고교 가부시키가이샤 신경 재생 및/또는 보호제
JP5630264B2 (ja) * 2008-06-06 2014-11-26 小野薬品工業株式会社 膀胱排尿筋収縮および尿道括約筋弛緩剤
US8410281B2 (en) * 2009-06-10 2013-04-02 Ono Pharmaceutical Co., Ltd. Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
TWI481401B (zh) 2010-01-27 2015-04-21 Takeda Pharmaceutical 藥劑
JP6131956B2 (ja) * 2012-08-31 2017-05-24 小野薬品工業株式会社 アミン塩とその結晶
KR20150130326A (ko) * 2013-03-15 2015-11-23 카이맨 케미칼 컴파니 인코포레이티드 Ep4-매개 질환 및 병태의 치료에서 사용하기 위한 ep4 수용체 선택적 효현제로서 락탐 화합물
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
AU2018396402C1 (en) 2017-12-25 2021-03-18 Asahi Kasei Pharma Corporation Nitrogen-containing 6-membered cyclic compound
SG11202101033YA (en) * 2018-07-31 2021-03-30 Ono Pharmaceutical Co Benzene derivative

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5525602B2 (ko) 1973-05-10 1980-07-07
US4087620A (en) 1975-07-17 1978-05-02 Ono Pharmaceutical Company 15-Cycloalkyl-prostaglandin derivatives
JPS5231404A (en) 1975-09-03 1977-03-09 Toyo Tire & Rubber Co Ltd Safe pneumatic tyre
JPS6036422B2 (ja) 1979-01-29 1985-08-20 小野薬品工業株式会社 プロスタグランジン類似化合物及びその製造方法
JPS60197667A (ja) 1984-03-19 1985-10-07 Ono Pharmaceut Co Ltd ６―ケト―プロスタグランジン類似化合物及びその製造方法
JPS6152146A (ja) 1984-08-20 1986-03-14 Matsushita Electric Ind Co Ltd 電動機
JP3774907B2 (ja) 1993-12-09 2006-05-17 小野薬品工業株式会社 ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
JPH07233145A (ja) 1993-12-27 1995-09-05 Taisho Pharmaceut Co Ltd プロスタグランジンｅ１アミド類縁体
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
JPH08239356A (ja) 1994-12-28 1996-09-17 Ono Pharmaceut Co Ltd ナフチルオキシ酢酸誘導体およびそれを有効成分として含有する医薬
EP0845451A4 (en) 1995-07-26 1999-10-13 Ono Pharmaceutical Co NAPHTHYLOXYACETIC ACID DERIVATIVES AND MEDICINAL PRODUCTS INTEGRATING THESE DERIVATIVES AS ACTIVE INGREDIENTS
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
JP3865842B2 (ja) 1996-12-09 2007-01-10 大正製薬株式会社 プロスタグランジンｅ１類縁体
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
PT1008588E (pt) 1997-02-10 2003-09-30 Ono Pharmaceutical Co Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
JPH1112249A (ja) 1997-06-24 1999-01-19 Taisho Pharmaceut Co Ltd プロスタグランジンｅ類縁体
JPH11130678A (ja) 1997-08-27 1999-05-18 Kaken Pharmaceut Co Ltd 神経圧迫による神経障害改善剤
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
ATE260254T1 (de) 1997-12-25 2004-03-15 Ono Pharmaceutical Co Omega-cycloalkyl-prostaglandin e2 derivate
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
US6376533B1 (en) 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
ATE500218T1 (de) 2001-07-23 2011-03-15 Ono Pharmaceutical Co Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
US7402605B2 (en) * 2002-03-05 2008-07-22 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
DE10226390B4 (de) 2002-06-13 2004-07-22 Siemens Ag Resistive Strombegrenzereinrichtung mit supraleitender Leiterbahn und nicht-supraleitendem Shunt
AU2002345285A1 (en) * 2002-07-11 2004-02-02 Nokia Corporation Method and device for automatically changing a digital content on a mobile device according to sensor data
EP1586564B1 (en) 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
ES2305779T3 (es) 2003-03-03 2008-11-01 Laboratoires Serono Sa Derivados de g-lactama como agonistas de prostaglandinas.
JPWO2004089411A1 (ja) * 2003-04-03 2006-07-06 小野薬品工業株式会社 脊柱管狭窄症治療剤
CA2529123A1 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
EP1707208A4 (en) * 2003-12-05 2010-03-17 Ono Pharmaceutical Co PROMOTER OF BLOOD FLOW IN THE TISSUES OF THE HORSE TAIL
WO2005061492A1 (ja) * 2003-12-22 2005-07-07 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれらを有効成分とする薬剤
US7858610B2 (en) * 2004-08-10 2010-12-28 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist
EP1806148A4 (en) * 2004-10-22 2009-12-02 Ono Pharmaceutical Co THERAPEUTIC PREPARATION FOR INHALATION
KR101320810B1 (ko) * 2005-06-03 2013-10-21 오노 야꾸힝 고교 가부시키가이샤 신경 재생 및/또는 보호제

Also Published As

Publication number Publication date
US8404858B2 (en) 2013-03-26
KR20080016926A (ko) 2008-02-22
TWI404529B (zh) 2013-08-11
CA2610692A1 (en) 2006-12-07
CN101237885B (zh) 2011-01-19
EP2308510A1 (en) 2011-04-13
TW200716103A (en) 2007-05-01
US20130143934A1 (en) 2013-06-06
JP5040650B2 (ja) 2012-10-03
EP2494990A1 (en) 2012-09-05
CN101237885A (zh) 2008-08-06
AU2006253356B2 (en) 2011-12-01
AU2006253356A1 (en) 2006-12-07
KR101320810B1 (ko) 2013-10-21
ZA200710414B (en) 2008-11-26
EP1886693A1 (en) 2008-02-13
JPWO2006129788A1 (ja) 2009-01-08
RU2007148992A (ru) 2009-06-27
EP1886693A4 (en) 2010-03-03
IL187840A0 (en) 2008-03-20
IL207325A0 (en) 2011-08-01
NZ563863A (en) 2011-02-25
IL187840A (en) 2011-12-29
US20110059920A1 (en) 2011-03-10
CA2610692C (en) 2014-11-25
WO2006129788A1 (ja) 2006-12-07
EP2308510B1 (en) 2016-03-16
BRPI0611079A2 (pt) 2010-08-03
US7863263B2 (en) 2011-01-04
US20090227644A1 (en) 2009-09-10
RU2420316C2 (ru) 2011-06-10
ES2572755T3 (es) 2016-06-02

Similar Documents

Publication Publication Date Title
NO20076232L (no) Middel for regenerering og/eller besyttelse av nerver
WO2018106839A3 (en) Systems and methods for treating neurological disorders
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
NO20083240L (no) Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia
BRPI0512161A (pt) métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2010021693A3 (en) Mif modulators
TNSN08382A1 (en) New compounds
NO20064792L (no) Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
EA200900970A1 (ru) Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтина
AR052955A1 (es) Producto de combinacion de o- desmetilvanlafaxina y bazedoxifeno y usos del mismo
BR112017009053A2 (pt) dispositivo para inibição da atividade neural de um nervo do seio carotídeo ou corpo carotídeo, método para tratamento de uma condição, forma de onda elétrica neuromodulatória, e, uso de um dispositivo de neuromodulação para o tratamento de uma condição.
NO20065768L (no) Karbonsamid-opioidforbindelser
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2014144606A3 (en) Methods of treating muscular dystrophy
NO20052646L (no) Method of treating cognitive decline due to sleep deprivation and stress
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
EP3712264A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2009067690A3 (en) Methods for safe and effective treatment using oxazaphosphorine drugs
CA2986891C (en) Compositions for use in treating parkinson&#39;s disease and related disorders
WO2015165948A3 (en) Compositions for the treatment of diabetic neuropathies
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application